How should resuscitative endovascular balloon occlusion of the aorta (REBOA) be performed during cardiopulmonary resuscitation (CPR) in adult trauma patients with massive non‑compressible torso hemorrhage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

REBOA During CPR in Trauma Patients

REBOA may be considered during CPR for traumatic cardiac arrest from non-compressible torso hemorrhage, but current evidence shows it does not improve mortality and may increase complications compared to standard resuscitation alone. 1, 2

Guideline-Based Recommendation

The European trauma guideline states that resuscitative endovascular balloon occlusion of the aorta may be considered in patients with non-compressible life-threatening traumatic hemorrhage 1. However, this recommendation predates the most recent high-quality evidence showing potential harm.

Critical Evidence Analysis

The 2026 systematic review and meta-analysis—the highest quality evidence available—reveals important nuances 3:

  • In hemorrhagic shock (not yet arrested): REBOA shows mortality benefit (OR: 0.18,95% CI: 0.12-0.28)
  • In cardiac arrest: Benefit is substantially reduced (OR: 0.32,95% CI: 0.15-0.69)
  • Complications increase significantly: 7.8-fold higher complication rates with REBOA
  • Early mortality shows greatest effect, but overall in-hospital mortality benefit diminishes

Most critically, the 2026 narrative review analyzing the only randomized controlled trial to date found that REBOA in hemodynamically unstable patients does not confer mortality benefit and may increase mortality compared to standard care 2.

When to Consider REBOA During CPR

Proceed with REBOA if ALL criteria met:

  • Witnessed traumatic cardiac arrest with short downtime (<10 minutes)
  • Suspected non-compressible torso hemorrhage below the diaphragm (abdominal/pelvic)
  • Experienced team available with established REBOA protocols
  • Definitive hemorrhage control (OR or interventional radiology) immediately accessible
  • No severe traumatic brain injury (contraindication to prolonged hypoperfusion)

Do NOT use REBOA if:

  • Prolonged arrest (>10-15 minutes)
  • Compressible hemorrhage amenable to direct pressure/packing
  • No immediate access to definitive hemorrhage control
  • Inexperienced team or first-time attempt during arrest

Technical Execution During CPR

Access method: Ultrasound-guided common femoral artery access is superior to landmark technique 4:

  • 55% first-pass success with ultrasound vs. 45% requiring multiple attempts with landmarks
  • Reduces access time by 1-6 minutes
  • Decreases vascular complications from 9.2% to 5.5%
  • Use 7 Fr sheath (associated with fewer complications)

Balloon placement during CPR:

  • Zone I (supraceliac) for abdominal/pelvic hemorrhage during arrest 5
  • Inflate balloon during ongoing chest compressions
  • Target systolic BP >80 mmHg if return of spontaneous circulation (ROSC) achieved
  • Limit occlusion time to <40 minutes to minimize ischemia-reperfusion injury 6

Realistic Outcomes

Case series data shows sobering reality 7, 5:

  • 58% of arrest patients achieve ROSC with REBOA
  • Only 38% of those with ROSC survive to OR
  • Overall 90% mortality in traumatic arrest patients receiving REBOA
  • Survivors who achieve ROSC can have full neurologic recovery

Critical Pitfalls

  1. Delayed access attempts: Multiple failed percutaneous attempts increase mortality—convert to cutdown early if not successful within 2 attempts
  2. Prolonged occlusion: >60 minutes causes irreversible ischemic injury, acute kidney injury, and compartment syndrome
  3. Using REBOA as substitute for definitive care: It's a bridge only—OR/IR must be immediately available
  4. Inappropriate patient selection: REBOA during prolonged arrest wastes time better spent on resuscitative thoracotomy or termination

Alternative Approach

Resuscitative thoracotomy with aortic cross-clamp remains the standard for traumatic arrest when REBOA expertise is unavailable or access cannot be rapidly obtained. The 2026 meta-analysis shows REBOA superiority only when performed by experienced teams within structured trauma systems 3.

In most cardiac arrest scenarios, standard ACLS with rapid transport to definitive hemorrhage control is more appropriate than attempting REBOA, given the lack of mortality benefit and increased complications 2.

References

2
Research

Resuscitative endovascular balloon occlusion of the aorta in trauma patients: Past, present, and future.

Chinese journal of traumatology = Zhonghua chuang shang za zhi, 2026

Related Questions

What is the design, eligibility criteria, interventions, and outcomes of the CPReboa trial evaluating Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) as an adjunct to standard cardiopulmonary resuscitation in adults with refractory non‑traumatic cardiac arrest?
What are the outcomes and potential complications of using Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in hemodynamically unstable patients with a ruptured aorta?
With elevated thyroid‑stimulating hormone, low‑normal free thyroxine, and bradycardia, should I start levothyroxine (Synthroid)?
Can I give telmisartan 40 mg once daily and sitagliptin 50 mg once daily together with metformin 500 mg twice daily, and repeat fasting blood glucose after one month?
What is the recommended cefepime (2 g) and tazobactam (250 mg) dosing regimen for an adult with a lung infection and normal renal function?
If blood glucose remains uncontrolled, can I add dapagliflozin 10 mg once daily to a regimen of telmisartan 40 mg daily, sitagliptin 50 mg daily, and metformin 500 mg twice daily, provided the patient has adequate renal function (eGFR ≥ 45 mL/min/1.73 m²)?
What are the stages of the Fontaine classification for peripheral arterial disease of the lower limbs?
What is the recommended salbutamol dose for acute bronchospasm (inhalation, nebulisation, oral, and intravenous) across different age groups?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.